BlinkLab

BlinkLab EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of BlinkLab (BB1.AX) as of Nov 2, 2026 is -14.20. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -20.99 — a change of -32.37% (higher).

EV/EBIT

-14.20

YoY

-32.37%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of BlinkLab is 2026 -14.20 . EV/EBIT (Enterprise Value to EBIT) of BlinkLab was 2025 -20.99 . It decreases by -32.37% higher compared to the previous year.

The BlinkLab EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2022
-247.57 AUD
Jan 1, 2023
-177.19 AUD
Jan 1, 2024
-68.40 AUD
Jan 1, 2025
-20.99 AUD
Jan 1, 2026
-14.20 AUD
The BlinkLab EV/EBIT history
YEAREV/EBITYoY
-14.20-32.37%
-20.99-69.31%
-68.40-61.40%
-177.19-28.43%
-247.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BlinkLab Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides BlinkLab's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates BlinkLab's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots BlinkLab's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if BlinkLab grows earnings faster than its peers.

BlinkLab Stock analysis

What does BlinkLab do? BlinkLab Ltd offers the BlinkLab Dx system, comprising the BlinkLab App and BlinkLab Portal, to conduct neurobehavioral tests for diagnosing neurological disorders. The BlinkLab App enables patients, caregivers, and parents to complete tests in real time, while the BlinkLab Portal provides secure database management, CMS, and tools for customizing neurometric tests, data analysis, and visualization. The company generates revenue through the sale of these products to healthcare providers, research institutions, and clinics seeking cost-effective diagnostic solutions for neurological and psychiatric conditions. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, serve as biomarkers for such disorders, making the system valuable for early detection and monitoring. Healthcare providers, research institutions, and clinics purchase the BlinkLab Dx system to integrate objective neurobehavioral testing into their diagnostic workflows. The BlinkLab App collects real-time data from test subjects, and the BlinkLab Portal allows for comprehensive data management and analysis, supporting both clinical and research applications. The company’s focus on biomarkers like EBC, PPI, and habituation of eye blink response positions it as a key tool for diagnosing disorders such as schizophrenia, ADHD, and autism spectrum disorders, which are increasingly recognized in clinical practice. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, are marketed as objective biomarkers for neurological and psychiatric disorders. By leveraging mobile technology, BlinkLab Ltd provides a cost-effective alternative to traditional diagnostic methods, appealing to institutions looking to streamline their diagnostic processes. The company’s revenue model relies on selling the BlinkLab App and Portal as integrated solutions, with no mention of additional services or third-party partnerships in the business description. BlinkLab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BlinkLab stock

EV/EBIT (Enterprise Value to EBIT) of BlinkLab is -14.20 in 2026.

EV/EBIT (Enterprise Value to EBIT) of BlinkLab changed from -20.99 to -14.20, representing a -32.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) BlinkLab since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s BlinkLab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BlinkLab

All Key Metrics — BlinkLab